697287-41-5

Usage

Uses

1. Used in Pharmaceutical Applications:
(S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)acrylamide is used as a potent KCNQ2 opener for inhibiting induced hyperexcitability of rat hippocampal neurons. Its application in this field is due to its ability to reduce neuronal hyperexcitability, which can be beneficial in treating neurological disorders associated with abnormal neuronal activity.
2. Used in Neuroscientific Research:
In the field of neuroscience, (S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)acrylamide serves as a valuable tool for studying the role of KCNQ2 channels in neuronal function and their potential as therapeutic targets for various neurological conditions.
3. Used in Drug Development:
(S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)acrylamide can be utilized in the development of new drugs targeting KCNQ2 channels, which may have applications in treating epilepsy, migraines, and other conditions characterized by neuronal hyperexcitability.
4. Used in Chemical Synthesis:
As a complex organic molecule, (S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)acrylamide may also find use in chemical synthesis for creating novel compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C23H25FN2O2/c1-16(25-23(27)11-9-18-4-2-3-5-20(18)24)19-8-10-22-21(14-19)26(12-13-28-22)15-17-6-7-17/h2-5,8-11,14,16-17H,6-7,12-13,15H2,1H3,(H,25,27)/b11-9+/t16-/m0/s1

Upstream product

• 7051-34-5 cyclopropylcarbinyl bromide 
• 697287-42-6 (+/-)-N-[1-(3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)acrylamide 
• 33574-02-6 cyclopropylmethyl iodide 
• 26518-71-8 6-acetyl-4H-benzo[1,4]oxazin-3-one 
• 477312-20-2 6-(1-hydroxyimino-ethyl)-4H-benzo[1,4]oxazin-3-one 
• 477312-23-5 (+/-)-1-(3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)ethylamine 
• 159459-52-6 6-[1-aminoethyl]-2H-1,4-benzoxazin-3(4H)-one 
• 18944-77-9 2-fluorocinnamic acid 

Relevant academic research and scientific papers

(S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl] -3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons

(S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl] -3-(2-fluoro-phenyl)-acrylamide ((S)-2) was identified as a potent and efficacious KCNQ2 opener. This compound demonstrated significant activity in reducing neuronal hyperexcitabil

Cinnamide derivatives as KCNQ potassium channel modulators

There is provided novel cinnamide derivatives of Formula I wherein R is C1-4 alkyl or trifluoromethyl; R1 is selected from the group consisting of pyridinyl, quinolinyl, thienyl, furanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, chromanyl, indanyl, biphenylyl, phenyl and substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected-from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R2 and R3 are each independently selected from the group consisting of hydrogen, C1-4 alkyl, and halogen; R4 is selected from the group consisting of di(C1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of C1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; R5 is hydrogen, chloro or fluoro; or R4 and R5 taken together are —CH═CH—CH═CH— or —X(CH2)mY— in which X and Y are each independently selected from the group consisting of CH2, (CH2)nN(R9)— and O, wherein m is 1 or 2; n is 0 or 1; and R6, R7, and R8 are each independently selected from hydrogen, chloro and fluoro; and R9 is selected from the group consisting of hydrogen, C1-4 alkyl, hydroxyethyl, C1-4 alkoxyethyl, cyclopropylmethyl, —CO2(C1-4alkyl), and —CH2CH2NR10R11 in which R10 and R11 are each independently hydrogen or C1-4 alkyl, which are openers of the KCNQ potassium channels and are useful in the treatment of disorders which are responsive to the opening of the KCNQ potassium channels.